FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists
Summary
An FDA advisory committee voted to allow certain peptides to be made by compounding pharmacies, even though some FDA scientists expressed concerns about their safety and effectiveness. The decision came after public comments and presentations about peptides like BPC-157, KPV, TB-500, and MOTS-c.Key Facts
- The FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to add peptides to the list of substances allowed for compounding.
- Compounding pharmacies create customized medications for patients.
- Some FDA scientists opposed the addition, citing a lack of clear benefits.
- The peptides discussed include BPC-157, KPV, TB-500, and MOTS-c.
- Public comments were heard before the vote took place.
- The decision affects how these peptides can be produced and used in medical treatments.
- Compounding is regulated to ensure safety, but concerns remain over these specific peptides’ effects.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
